2016 Fiscal Year Final Research Report
A biomarker study of heregulin to predict efficacy of anti-HER2 drugs in HER2-positive breast and gastric cancer
| Project/Area Number |
26430174
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Kindai University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | HER2 / 乳癌 / 胃癌 / 化学療法 / 分子標的薬 / 薬剤耐性 / ヘレギュリン |
|---|
| Outline of Final Research Achievements |
Recombinant heregulin desensitized HER2 positive breast or gastric cancer cell lines to trastuzumab, lapatinib, but not to T-DM1. The SKBR3 and N87 cells were transfected with heregulin gene and sensitivities of those cell to each drug were evaluated. The transfectants were desensitized to trastuzumab and lapatinib, but not T-DM1. The resuls were likewise in the xenograft model innoculated with the heregulin-transfected N87 cells. In clinical specimens obtained from patinets with breast or gastric cancer who became resistant to trastuzumab, the expression levels of heregulin protein were upregulated compared to the pre-treatment samples, suggesting that heregulin is involved in the acquired resistance to anti-HER2 therapy, other than T-DM1.
|
| Free Research Field |
臨床腫瘍学
|
